AZN (AstraZeneca PLC) Trailing twelve months financial, business summary

AstraZeneca PLC

AZN

164.77 (1.94%) 3.20

Market cap

$255.56(B)

Earnings date

Oct-30-2026

Sector

Health Care

Industry

Pharmaceuticals

AstraZeneca PLC a biopharmaceutical company focuses on the discovery development manufacture and commercialization of prescription medicines. The company offers Imjudo Datroway Iressa Tagrisso Imfinzi Lynparza Calquence Enhertu Orpathys Truqap Zoladex Faslodex Crestor Andexxa Onglyza Symlin XIGDUO XR Atacand Atacand HCT Atacand Plus Farxiga/Forxiga Plendil Modip Splendil Munobal Flodil Tenormin Tenormine Prenormine Atenol Zestril Brilinta/Brilique Komboglyze Qtern Wainua Byetta Lokelma Seloken ZOK Toprol-XL Betaloc ZOK XIGDUO Accolate Accoleit Vanticon Bricanyl Respules Eklira Genuair/Tudorza/Bretaris Pulmicort Turbuhaler Symbicort Turbuhaler Airsupra Bricanyl Turbuhaler Fasenra Rhinocort Tezspire Bevespi Aerosphere Daliresp/Daxas Oxis Turbuhaler Saphnelo Breztri Aerosphere Duaklir Genuair Pulmicort Respules and Symbicort pMDI. It also provides Beyfortus Kavigale Evusheld Fluenz/FluMist Synagis Kanuma Ultomiris Koselugo Voydeya Soliris Strensiq Nexium and other medicines. The company offers its products for ocology cardiovascular renal and metabolism respiratory & immunology vaccines and immune and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom the Americas rest of Europe Asia Africa and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge the United Kingdom.

EV: $288.92(B)

Total Equity: $50.37(B)

Debt/Equity: 0.64

Dividend/share: $3.2

Div. yield: 1.96%

P/E: 24.45

Forward P/E: 16.11

P/FCF: 23.95

P/S: 4.16

P/B: 5.08

EPS: $6.7

EPS (fwd): $10.2

FCF/share: $6.9

Revenue/share: $39.6

Book value/share: $32.4

ROIC: 12.5%

ROA: 8.6%

ROE: 21.7%

Margins: Gross | Op. | Net

81.7% | 22.0% | 17.0%

0.0%of Portfolio

My holdings

Day change

Total change

Overview Valuation Growth Financials & KPIs Competitors & Peer Comparison Ownership Tools All

PEvaluation

34%

$109

Based on a fair P/E of 9.9x and
forward EPS of $11.10

Valuation summary

Min—

Max—

Average—

Median—

Valuation comparison

Quality checklist score

5/8

Based on your selected metrics.

ROIC > 10% Debt/Equity < 1 Net Margin > 10% Past Net Income CAGR > 0% Est. EPS Growth > 5%

5Y Shares Out Change < 0% Current Ratio > 1 Quick Ratio > 1

TTM Financials

Income (TTM)

Revenue$61.37(B)

Gross profit$50.13(B)

EBITDA$19.90(B)

Net income$10.45(B)

Gross margin81.7%

Operating margin22.0%

Net margin17.0%

Shares outstanding1.55(B)

Balance sheet

Total assets$115.83(B)

Current assets$27.96(B)

Total liabilities$65.46(B)

Current liabilities$31.55(B)

Cash & Short-term inv.$4.97(B)

Long-term debt$23.69(B)

Total intangibles$58.90(B)

PP&E$16.30(B)

Cash flow (TTM)

FCF$10.67(B)

CapEx$-3.03(B)

Dividends paid$-4.78(B)

Stock issued$44.00(M)

Stock repurchased$-690.00(M)

Stock-based comp.$719.00(M)

Debt issued$2.95(B)

Debt repaid$-4.84(B)

Per share data (TTM)

Price

$165

Income

Revenue

$39.6•4.2x|24.0%

Gross profit

$32.3•5.1x|19.6%

Earnings (EPS)

$6.74•24.4x|4.1%

Cash flow

FCF

$6.88•23.9x|4.2%

Stock-based comp.

$0.46•355.4x|0.3%

CapEx

$1.95•84.3x|1.2%

Dividend

$3.23•51.0x|2.0%

Balance sheet

Total assets

$74.7•2.2x|45.3%

Total liabilities

$42.2•3.9x|25.6%

Book value

$32.4•5.1x|19.7%

Cash & ST inv.

$3.20•51.4x|1.9%

Debt

$15.3•10.8x|9.3%

Forward earnings

EPS FY+1

$10.2•16.1x|6.2%

EPS FY+2

$11.4•14.5x|6.9%

EPS FY+3

$12.7•13.0x|7.7%

EPS FY+4

$14.3•11.5x|8.7%

EPS FY+5

$15.8•10.4x|9.6%

Forward FCF

FCF FY+1

$5.65•29.2x|3.4%

FCF FY+2

$8.90•18.5x|5.4%

FCF FY+3

$10.3•16.1x|6.2%

FCF FY+4

$11.1•14.8x|6.8%

FCF FY+5

$12.4•13.3x|7.5%

Summary

	Low	Avg	High	#
FY+1	10.0	10.2	10.6	23
FY+2	10.9	11.4	12.0	23
FY+3	11.4	12.7	13.8	19
FY+4	11.8	14.3	16.1	10
FY+5	12.3	15.8	18.5	10

About

Terms & privacy

Price charts & news courtesy of TradingView

Blog

Contact

First Stage Duration: 5 Years

Starting Free Cash Flow
First Stage Growth Rate
Low Mid High
Terminal Growth Rate
Low Mid High
Discount Rate

Forecast years: 5 Years

Terminal Growth Rate
Low Mid High
Discount Rate

Forecast years: 5 Years

Exit FCF Multiple
Low Mid High
Discount Rate

Annual Dividend
First Stage Length (Years): 0 Years

First Stage Growth Rate
Low Mid High
Final Growth Rate
Low Mid High
Discount Rate

Forecast years: 5 Years

Starting EPS
EPS Growth Rate
Low Mid High
Final P/E
Low Mid High
Discount Rate

Market cap

Earnings date

Category

Sector

Industry

TTM Financials

Income (TTM)

Balance sheet

Cash flow (TTM)

Per share data (TTM)

Summary

PEvaluation

Fair P/E

Margin of safety

EPS

Market Model

Economic moat: None/narrow

EPS Estimates

Analyst Price Targets

Analyst Recommendations

2-stage DCF

Discounted Cash Flow

Free cash flow estimates:

Discounted Cash Flow (exit mult.)

Free cash flow estimates:

Dividend Discount Model

EPS Growth

Revenue Growth Valuation

Peter Lynch Fair Value

Graham Formula

Forecast Years: 10 Years

Base Revenue
Revenue Growth Rate
Low Mid High
Final Net Margin
Low Mid High
Final P/E Ratio
Low Mid High
Discount Rate

Earnings Per Share
EPS Growth (7-10 years)
Low Mid High
Government Bond Rate